Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer

Summary

This phase II trial studies how well dasatinib works in treating patients with ovarian, fallopian tube, endometrial, or peritoneal cancer that has come back or is persistent. Dasatinib may shrink patients' tumors by blocking some of the enzymes needed for cell growth.

Timeline

Start

2014-02-14

Primary completion

2017-02-06

Completion

2023-06-26

Outcome

Outcome not reported

Stopped: “Interim monitoring”

Drugs

Indications